Tag - Vicl

Allos Therapeutics Inc. (Nasdaq:ALTH), Amedisys Inc. (Nasdaq:AMED) and Novavax Inc. (Nasdaq:NVAX) are among the most actively traded companies in Thursday's trading among companies with market capitalizations under $1 billion.

Also included among the results: Vical Inc. (Nasdaq:VICL), China Natural Gas Inc. (Nasdaq:CHNG), Spectrum Pharmaceuticals Inc. (Nasdaq:SPPI), Sequenom Inc. (Nasdaq:SQNM), Century Aluminum Co. (Nasdaq:CENX) and Sanmina-SCI Corp. (Nasdaq:SANMD).

B. Riley & Co. downgraded footwear retailer The Finish Line, Inc. (Nasdaq: FINL) to “neutral” from “buy” with a target price of $15, from $13.

Vical Inc. (Nasdaq: VICL) reported that preliminary late-stage trial results showed a drug candidate successfully treated the blood flow disease ischemia by increasing the size of blood vessels.

These are the biggest percentage losers in Tuesday's trading among companies with market capitalizations under $500 million:

Allos Therapeutics, Inc. (Nasdaq: ALTH) reported its clinical trial for Efaproxyn failed to show that the drug improved survival in women with breast cancer that spread to the brain.

EPIX Pharmaceuticals, Inc. (Nasdaq: EPIX) announced that it has received a negative response from the FDA regarding the company's appeal for immediate approval of Vasovist, a treatment used to diagnose vascular disease.

Syntax-Brillian Corp. (Nasdaq: BRLC) is launching its new 65” LCD high-definition television today.

Vical Inc. (Nasdaq: VICL) reported that preliminary late-stage trial results showed a drug candidate successfully treated the blood flow disease ischemia by increasing the size of blood vessels.

Analyst William Ho raised his rating on Acorda Therapeutics Inc. (Nasdaq: ACOR) to “buy” from “neutral.”

The following are the most actively traded companies in Tuesday pre-market trading among those with market capitalizations under $500 million:

American Technical Ceramics Corp. (AMEX: AMK) reported it agreed to be acquired by AVX Corp. (NYSE: AVX) for $24.75 per share, or about $231 million in cash, which represents a 47% premium to Friday’s closing price.

Vical Inc. (Nasdaq: VICL) said a trial of its gene-delivery technology reported positive results.

LMI Aerospace, Inc. (Nasdaq: LMIA) reported it plans to buy engineering services company D3 Technologies for $65 million in cash.

These are the biggest percentage gainers in Monday's trading among companies with market capitalizations under $500 million:

U.S. stocks opened close to the flat line following little news save for the latest corporate deal-making.

At 10:19 a.m. ET the Russell 2000 was down 4.73 points, or 0.56 percent, to 843.46. Dow Jones Industrial Average had lost 14.06 points, or 0.10 percent, to 13,625.42.

Australia’s BHP Billiton Ltd. (NYSE: BHP), the world’s largest mining company, is renewing its $40 billion bid for Pittsburgh, Pa.-based aluminum producer Alcoa Inc. (NYSE: AA), according to Britain’s The Times newspaper.

Elsewhere, General Electric Co. (NYSE: GE) may join forces with Pearson PLC, which publishes the Financial Times, to make an offer for Dow Jones & Company, Inc. (NYSE: DJ) that tops that of Rupert Murdoch’s News Corp. (NYSE: NWS), according to The Wall Street Journal.

The following were the most actively traded companies in Monday's trading among those with market capitalizations under $500 million:

Shares of Stemcells Inc. (Nasdaq: STEM) have appreciated on news this morning that the pharmaceutical company has successfully completed enrollment for a Phase I clinical trial of its treatment for Batten disease, a fatal disorder of the nervous systems. Shares are up $0.02, or 1%, to $2.46.

Shares of Canadian pharmaceutical company Labopharm Inc. (Nasdaq: DDSS) are higher following news over the weekend that it has received a notice of compliance from regulators for its pain management tablets and can now begin marketing. Shares are up $0.16, or 6%, to $2.89.

Shares of Vical Inc. (Nasdaq: VICL) are sagging despite news this morning that the San Diego-based pharmaceutical company has been awarded a three-year, $6 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) for a DNA vaccine manufacturing process.  Shares are down $0.05, or 1%, to $4.95.

Shares of Repligen Corp. (Nasdaq: RGEN) are trading higher following news this morning that the Waltham, Mass.-based pharmaceutical company has received a favorable ruling from the U.S. District Court for the District of Massachusetts on a patent infringement lawsuit involving ImClone Systems Inc. (Nasdaq: IMCL).

Houston-based Mitcham Industries expects to double its operating income in 2008, but fourth-quarter fiscal 2007 profit fell due to a production design problem.